Complete response to bicalutamide withdrawal prolonged for almost 2 years in patients with metastatic prostate cancer

Hiroshi Hongo, Takeo Kosaka, Mototsugu Oya

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This is the first case report describing a complete response to bicalutamide withdrawal that lasted for almost 2years in a patient with metastatic prostate cancer. An 80-year-old man who had prostate-specific antigen (PSA) level elevation (168.1ng/mL) visited our hospital in February 2010. Bone scintigraphy showed pelvic metastases. We started hormonal therapy with leuprorelin and bicalutamide. The PSA concentration decreased to <0.1ng/mL but started increasing again and reached 1.64ng/mL in October 2012, at which time bicalutamide administration was discontinued. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2years.

Original languageEnglish
Pages (from-to)150-151
Number of pages2
JournalUrology Case Reports
Volume2
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Leuprolide
Radionuclide Imaging
Neoplasm Metastasis
Bone and Bones
bicalutamide
Therapeutics

Keywords

  • Antiandrogen withdrawal syndrome
  • Bicalutamide
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

@article{063ce720bf4d449eb62f457615c4df11,
title = "Complete response to bicalutamide withdrawal prolonged for almost 2 years in patients with metastatic prostate cancer",
abstract = "This is the first case report describing a complete response to bicalutamide withdrawal that lasted for almost 2years in a patient with metastatic prostate cancer. An 80-year-old man who had prostate-specific antigen (PSA) level elevation (168.1ng/mL) visited our hospital in February 2010. Bone scintigraphy showed pelvic metastases. We started hormonal therapy with leuprorelin and bicalutamide. The PSA concentration decreased to <0.1ng/mL but started increasing again and reached 1.64ng/mL in October 2012, at which time bicalutamide administration was discontinued. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2years.",
keywords = "Antiandrogen withdrawal syndrome, Bicalutamide, Prostate cancer",
author = "Hiroshi Hongo and Takeo Kosaka and Mototsugu Oya",
year = "2014",
doi = "10.1016/j.eucr.2014.06.002",
language = "English",
volume = "2",
pages = "150--151",
journal = "Urology Case Reports",
issn = "2214-4420",
publisher = "Elsevier Saunders",
number = "5",

}

TY - JOUR

T1 - Complete response to bicalutamide withdrawal prolonged for almost 2 years in patients with metastatic prostate cancer

AU - Hongo, Hiroshi

AU - Kosaka, Takeo

AU - Oya, Mototsugu

PY - 2014

Y1 - 2014

N2 - This is the first case report describing a complete response to bicalutamide withdrawal that lasted for almost 2years in a patient with metastatic prostate cancer. An 80-year-old man who had prostate-specific antigen (PSA) level elevation (168.1ng/mL) visited our hospital in February 2010. Bone scintigraphy showed pelvic metastases. We started hormonal therapy with leuprorelin and bicalutamide. The PSA concentration decreased to <0.1ng/mL but started increasing again and reached 1.64ng/mL in October 2012, at which time bicalutamide administration was discontinued. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2years.

AB - This is the first case report describing a complete response to bicalutamide withdrawal that lasted for almost 2years in a patient with metastatic prostate cancer. An 80-year-old man who had prostate-specific antigen (PSA) level elevation (168.1ng/mL) visited our hospital in February 2010. Bone scintigraphy showed pelvic metastases. We started hormonal therapy with leuprorelin and bicalutamide. The PSA concentration decreased to <0.1ng/mL but started increasing again and reached 1.64ng/mL in October 2012, at which time bicalutamide administration was discontinued. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2years.

KW - Antiandrogen withdrawal syndrome

KW - Bicalutamide

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84906502928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906502928&partnerID=8YFLogxK

U2 - 10.1016/j.eucr.2014.06.002

DO - 10.1016/j.eucr.2014.06.002

M3 - Article

AN - SCOPUS:84906502928

VL - 2

SP - 150

EP - 151

JO - Urology Case Reports

JF - Urology Case Reports

SN - 2214-4420

IS - 5

ER -